Market Access in Spain

Market Access Overview

Sample information taken from our MAP Spain section

The main objectives of market access are to facilitate the introduction of new medicines or medical devices into the market and to ensure that new medicines or medical devices are available to patients when a clinician believes that it is clinically appropriate. This involves many aspects such as evidence submission, optimal reimbursement schemes, price negotiations, incorporation into formularies, etc. Each CCAA provides universal, comprehensive care and full access to health services such as: hospitals, family doctors and emergency services.

MAP Spain

Unlocked PDF copies of flowcharts and supporting presentations are available to MAP Online members

.………………………………………….Join MAP to find out more

Reimbursement

AEMPS, operating under the Ministry of Health, is responsible for deciding whether a drug is reimbursed or not, based on five major aspects:

  1. Severity, duration and sequels of the diseases for which the drug is indicated
  2. Therapeutic and social utility of the drug
  3. ………………………………………….Join MAP to find out more
  4. ………………………………………….Join MAP to find out more
  5. ………………………………………….Join MAP to find out more

Due to the devolved healthcare system in Spain there are three different health technology appraisal (HTA) levels:

Overview

Reimbursement Overview

Screenshot 2016-05-18 18.02.03
………………………………………….Join MAP to find out more

National Level

………………………………………….Join MAP to find out more

Regional Level

………………………………………….Join MAP to find out more

Hospitals

………………………………………….Join MAP to find out more

If what you need is not already on MAP, we will complete the additional work, usually at no extra charge

Positive MAP Insights
Interested in what MAP has to offer? Get in touch to talk to one of our team members or to schedule a live web demo.

Do you think there is something missing or wrong with this page? Please let us know by using this form and we will address any issues ASAP.